ADRB2 Gene

<div class=“infobox infobox-gene”> <table> <tr><th colspan=“2” style=“background:#4477AA; color:white;”>ADRB2</th></tr> <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr> <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr> <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr> <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr> <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr> <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr> <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr> <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer’s Disease, Parkinson’s Disease, Asthma, COPD, Heart Failure</td></tr> </table> </div>

Overview

ADRB2 encodes the β2-adrenergic receptor (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease[@lefkowitz2014][@formoterol2018].

The β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].

Molecular Biology and Structure

Gene Organization

The ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:

TATA box: Core promoter element
CRE elements: cAMP response elements for regulated expression
AP-1 sites: Responsive to growth factors and cytokines
GRE: Glucocorticoid response elements
NF-κB elements: Allows inflammatory regulation

Multiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].

Protein Structure

The β2-adrenergic receptor has classical GPCR architecture:

N-terminal extracellular domain (1-39 aa): Contains two N-linked glycosylation sites
Transmembrane domains (TM1-TM7): Seven α-helices forming the ligand-binding pocket
Extracellular loops (ECL1-ECL3): ECL2 contains a conserved disulfide bond
Intracellular loops (ICL1-ICL3): ICL3 is the primary G protein coupling domain
C-terminal tail (342-413 aa): Contains serine/threonine phosphorylation sites

The ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:

Asp113 in TM3 (counterion for catecholamine amine)
Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)
Phe282 (hydrophobic interactions with aromatic ring)

Splice Variants

Multiple splice variants of ADRB2 have been described:

β2-AR1: Full-length 413 aa (predominant)
β2-AR2: Alternative C-terminus
Truncated variants: May have distinct signaling properties

Signaling Pathways

Primary Gs-cAMP Pathway

Upon agonist binding:

Conformational change activates Gs protein
Gαs-GTP stimulates adenylyl cyclase
cAMP production increases
PKA activation leads to substrate phosphorylation
Physiological effects on muscle relaxation, glycogenolysis, gene transcription

Alternative Gi/o Coupling

In some cell types, β2-AR couples to Gi/o:

Inhibition of adenylyl cyclase reduces cAMP
βγ subunits activate PI3K pathways
Cell-type specificity determines coupling preference

β-Arrestin Pathways

β2-AR signals through β-arrestins independently of G proteins:

ERK1/2 activation via β-arrestin scaffolds
Akt activation through similar mechanisms
Receptor internalization and recycling
Biased signaling potential for drug design

Receptor Dynamics

β2-AR exhibits unique properties:

Constitutive activity: Some basal signaling without agonist
Inverse agonism: Some ligands reduce baseline activity
Allosteric modulators: Bind at distinct sites
Oligomerization: May form heteromers with other GPCRs

Role in Neurodegenerative Diseases

Alzheimer’s Disease

Memory Consolidation

β2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:

Hippocampal LTP: β2-AR activation enhances long-term potentiation
Memory enhancement: Agonists improve consolidation in multiple paradigms
cAMP/PKA/CREB pathway: Required for consolidation effects
Time window: Effects greatest during post-training period

The noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.

Amyloid Pathology

β2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:

APP processing: cAMP can influence α-secretase activity
Aβ production: Effects are context-dependent
Synaptic protection: β2-AR activation protects against Aβ-induced synaptic dysfunction
Neuronal survival: Anti-apoptotic signaling through PI3K/Akt

Neuroinflammation

β2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:

Microglial inhibition: β2-AR activation reduces pro-inflammatory cytokine release
TNF-α suppression: Reduces microglial activation
IL-1β and IL-6: Suppressed by β2-agonists
Therapeutic potential: Reduces neuroinflammation in AD models

Genetic Associations

Several studies link ADRB2 variants to AD risk[@mittal2017]:

Functional polymorphisms may alter receptor signaling
Population-specific effects observed in different cohorts
Gene-environment interactions with lifestyle factors

Parkinson’s Disease

Neuroprotection

β2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:

Dopaminergic neuron survival: Protects against MPTP and 6-OHDA toxicity
α-Synuclein effects: May reduce aggregation or toxicity
Anti-apoptotic signaling: Through cAMP/PKA and PI3K pathways
Anti-inflammatory: Microglial suppression

Clinical Trials

β2-agonists are being investigated for PD:

Formoterol: Long-acting β2-agonist in clinical trials
Safety profile: Generally well-tolerated
CNS penetration: A challenge for some compounds

Autonomic Function

β2-AR contributes to autonomic regulation:

Cardiac effects: Modulates heart rate and contractility
Blood pressure: Influences vascular tone
PD autonomic dysfunction: Relevant to non-motor symptoms

Stroke and Cerebral Ischemia

β2-AR activation provides neuroprotection in stroke models[@park2020]:

Infarct reduction: Reduces cerebral infarction
Anti-apoptotic: Promotes neuronal survival
Anti-inflammatory: Reduces post-ischemic inflammation
Angiogenesis: May promote recovery

Mood Disorders

The β2-adrenergic system is relevant to depression:

β2-AR downregulation: Seen in depression
Antidepressant effects: Some antidepressants affect β2-AR signaling
Therapeutic targeting: β2-agonists have been explored

Expression Pattern

Central Nervous System

In the brain, β2-AR is expressed in:

Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
Cerebral cortex: Pyramidal neurons in all layers
Cerebellum: Purkinje cells and granule cells
Amygdala: Principal neurons
Hypothalamus: Regulatory neurons
Basal forebrain: Cholinergic projection neurons

Peripheral Tissues

Highest peripheral expression:

Lungs: Bronchial smooth muscle (primary site)
Heart: Cardiac myocytes
Liver: Hepatocytes
Skeletal muscle: Muscle fibers
Adipose tissue: Brown and white adipocytes

Subcellular Localization

Plasma membrane: Primary location
Endosomal compartments: Internalized receptors
Nucleus: Some nuclear localization reported

Therapeutic Implications

Respiratory Diseases

β2-AR agonists are first-line treatments:

Drug	Type	Half-life	Clinical Use
Albuterol	SABA	4-6 hours	Acute asthma
Salmeterol	LABA	12 hours	Maintenance asthma
Formoterol	LABA	12 hours	Asthma, COPD
Indacaterol	LABA	24 hours	COPD maintenance

Neurodegeneration

Therapeutic strategies include:

Brain-penetrant agonists: Formoterol, arformoterol
β-arrestin biased ligands: G protein-independent effects
Allosteric modulators: Increase agonist potency
Combination approaches: With cholinesterase inhibitors

Cardiovascular

β2-AR agonists have limited cardiac use:

Acute decompensation: Rarely used due to β1 effects
Peripheral vasodilation: Some β2-agonists cause hypotension
Safety concerns: Tremor and tachycardia

Animal Models

Genetic Models

Adrb2 knockout mice: Viable with respiratory and metabolic phenotypes
Transgenic overexpression: Tissue-specific models
Humanized mice: For drug testing

Phenotypes

Respiratory: Altered bronchial responsiveness
Metabolic: Changes in glycogen metabolism
Cardiac: Mild cardiac phenotypes
Behavioral: Altered stress responses

Disease Models

Tested in:

MPTP-induced parkinsonism
6-OHDA lesion models
Transgenic AD models
Cerebral ischemia models

Pathway Diagram

flowchart TD
    A["Epinephrine<br/>Norepinephrine"] --> B["beta2-Adrenergic Receptor"]
    B --> C1["Gs Protein<br/>Coupling"]
    B --> C2["Gi Protein<br/>Coupling"]
    B --> C3["beta-Arrestin<br/>Pathway"]

    C1 --> D1["Adenylyl Cyclase<br/>up"]
    C1 --> D1
    D1 --> E1["cAMP<br/>up"]
    E1 --> F1["PKA<br/>Activation"]

    F1 --> G1["CREB<br/>Phosphorylation"]
    F1 --> G2["Synaptic<br/>Plasticity"]
    F1 --> G3["Gene<br/>Transcription"]
    F1 --> G4["Anti-inflammatory<br/>Response"]

    C2 --> D2["Adenylyl Cyclase<br/>down"]
    D2 --> E2["cAMP<br/>down"]
    E2 --> F2["betagamma -> PI3K/Akt"]

    C3 --> D3["beta-Arrestin<br/>Scaffold"]
    D3 --> E3["ERK1/2<br/>Activation"]
    D3 --> F3["Akt<br/>Activation"]

    G1 --> H["Memory<br/>Consolidation"]
    G2 --> H
    G3 --> I["Neuronal<br/>Survival"]
    G4 --> J["Neuroprotection"]

    style A fill:#0a1929,stroke:#333
    style B fill:#0a1929,stroke:#333
    style H fill:#0e2e10,stroke:#333
    style I fill:#0e2e10,stroke:#333
    style J fill:#0e2e10,stroke:#333

Key Publications

Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation[@lefkowitz2014]
Moreau et al., 2018 - Formoterol rescues memory in AD models[@formoterol2018]
Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons[@birmingham2019]
Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors[@galandrin2007]
Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization[@nichols2016]
Ibayashi et al., 2019 - Beta2-AR signaling in glial cells[@ibayashi2019]
Mittal et al., 2017 - ADRB2 polymorphisms and AD risk[@mittal2017]
Yan et al., 2019 - Beta2-agonists for PD disease modification[@yan2019]
Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity[@wang2018]
Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production[@chen2017]
Yang et al., 2016 - Beta2-AR and neuroinflammation in AD[@yang2016]
Liu et al., 2018 - Beta2-AR in PD models[@liu2018]
Xiao et al., 2019 - Beta-adrenergic signaling in the heart[@xiao2019]
Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection[@park2020]

External Links

Pathway Diagram

The following diagram shows the key molecular relationships involving ADRB2 Gene discovered through SciDEX knowledge graph analysis:

graph TD
    GABRA1["GABRA1"] -->|"associated with"| ADRB2["ADRB2"]
    CHAT["CHAT"] -->|"associated with"| ADRB2["ADRB2"]
    CYP2D6["CYP2D6"] -->|"associated with"| ADRB2["ADRB2"]
    APOE["APOE"] -->|"associated with"| ADRB2["ADRB2"]
    HMGCR["HMGCR"] -->|"associated with"| ADRB2["ADRB2"]
    OPRM1["OPRM1"] -->|"associated with"| ADRB2["ADRB2"]
    SLC30A8["SLC30A8"] -->|"associated with"| ADRB2["ADRB2"]
    COMT["COMT"] -->|"associated with"| ADRB2["ADRB2"]
    NBEA["NBEA"] -->|"associated with"| ADRB2["ADRB2"]
    HTR2C["HTR2C"] -->|"associated with"| ADRB2["ADRB2"]
    ADRA2A["ADRA2A"] -->|"associated with"| ADRB2["ADRB2"]
    BCHE["BCHE"] -->|"associated with"| ADRB2["ADRB2"]
    SLC6A2["SLC6A2"] -->|"associated with"| ADRB2["ADRB2"]
    SLC6A3["SLC6A3"] -->|"associated with"| ADRB2["ADRB2"]
    MAOB["MAOB"] -->|"associated with"| ADRB2["ADRB2"]
    style GABRA1 fill:#ce93d8,stroke:#333,color:#000
    style ADRB2 fill:#ce93d8,stroke:#333,color:#000
    style CHAT fill:#ce93d8,stroke:#333,color:#000
    style CYP2D6 fill:#ce93d8,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style HMGCR fill:#ce93d8,stroke:#333,color:#000
    style OPRM1 fill:#ce93d8,stroke:#333,color:#000
    style SLC30A8 fill:#ce93d8,stroke:#333,color:#000
    style COMT fill:#ce93d8,stroke:#333,color:#000
    style NBEA fill:#ce93d8,stroke:#333,color:#000
    style HTR2C fill:#ce93d8,stroke:#333,color:#000
    style ADRA2A fill:#ce93d8,stroke:#333,color:#000
    style BCHE fill:#ce93d8,stroke:#333,color:#000
    style SLC6A2 fill:#ce93d8,stroke:#333,color:#000
    style SLC6A3 fill:#ce93d8,stroke:#333,color:#000
    style MAOB fill:#ce93d8,stroke:#333,color:#000

ADRB2 Gene

Overview

Molecular Biology and Structure

Gene Organization

Protein Structure

Splice Variants

Signaling Pathways

Primary Gs-cAMP Pathway

Alternative Gi/o Coupling

β-Arrestin Pathways

Receptor Dynamics

Role in Neurodegenerative Diseases

Alzheimer’s Disease

Memory Consolidation

Amyloid Pathology

Neuroinflammation

Genetic Associations

Parkinson’s Disease

Neuroprotection

Clinical Trials

Autonomic Function

Stroke and Cerebral Ischemia

Mood Disorders

Expression Pattern

Central Nervous System

Peripheral Tissues

Subcellular Localization

Therapeutic Implications

Respiratory Diseases

Neurodegeneration

Cardiovascular

Animal Models

Genetic Models

Phenotypes

Disease Models

Pathway Diagram

Key Publications

See Also

External Links

Pathway Diagram